Laura K. Shawver

6.9k total citations · 2 hit papers
47 papers, 5.1k citations indexed

About

Laura K. Shawver is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Laura K. Shawver has authored 47 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Molecular Biology, 24 papers in Oncology and 12 papers in Cancer Research. Recurrent topics in Laura K. Shawver's work include Angiogenesis and VEGF in Cancer (12 papers), Cancer, Hypoxia, and Metabolism (11 papers) and HER2/EGFR in Cancer Research (7 papers). Laura K. Shawver is often cited by papers focused on Angiogenesis and VEGF in Cancer (12 papers), Cancer, Hypoxia, and Metabolism (11 papers) and HER2/EGFR in Cancer Research (7 papers). Laura K. Shawver collaborates with scholars based in United States, Germany and Japan. Laura K. Shawver's co-authors include Axel Ullrich, Karl H. Plate, B Millauer, Axel Ullrich, Dennis J. Slamon, Gerald McMahon, Laurie M. Strawn, Cho Tang, Li Sun and T. Annie T. Fong and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Laura K. Shawver

46 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant

1994 1.0k citations B Millauer, Laura K. Shawver et al. Nature profile →
SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.

1999 885 citations T. Annie T. Fong, Laura K. Shawver et al. PubMed profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Laura K. Shawver United States	26	3.4k	2.0k	1.2k	581	562	47	5.1k
Dale L. Ludwig United States	36	4.4k 1.3×	1.6k 0.8×	993 0.8×	689 1.2×	850 1.5×	91	5.9k
Francesco Hofmann Switzerland	30	4.2k 1.2×	1.4k 0.7×	1.0k 0.9×	312 0.5×	900 1.6×	56	5.9k
Tona M. Gilmer United States	30	4.0k 1.2×	3.8k 1.9×	850 0.7×	1.0k 1.8×	1.2k 2.2×	60	6.8k
Gabriella Zupi Italy	45	3.9k 1.1×	1.9k 1.0×	973 0.8×	220 0.4×	431 0.8×	161	5.6k
Dominic Fan United States	37	2.0k 0.6×	2.0k 1.0×	755 0.6×	284 0.5×	861 1.5×	72	4.1k
Peter Blume‐Jensen United States	18	3.3k 1.0×	1.3k 0.6×	454 0.4×	369 0.6×	561 1.0×	25	5.0k
Norma O’Donovan Ireland	36	2.2k 0.7×	2.3k 1.2×	838 0.7×	561 1.0×	637 1.1×	116	4.3k
Kathryn Packman United States	28	2.6k 0.8×	2.2k 1.1×	484 0.4×	296 0.5×	481 0.9×	65	3.9k
Francesca Carlomagno Italy	42	2.9k 0.9×	2.4k 1.2×	688 0.6×	165 0.3×	880 1.6×	92	6.2k
Antonella De Luca Italy	38	3.6k 1.0×	3.4k 1.8×	1.4k 1.2×	666 1.1×	1.7k 3.0×	102	6.8k

Countries citing papers authored by Laura K. Shawver

Since Specialization

Citations

This map shows the geographic impact of Laura K. Shawver's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura K. Shawver with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura K. Shawver more than expected).

Fields of papers citing papers by Laura K. Shawver

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura K. Shawver. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura K. Shawver. The network helps show where Laura K. Shawver may publish in the future.

Co-authorship network of co-authors of Laura K. Shawver

This figure shows the co-authorship network connecting the top 25 collaborators of Laura K. Shawver. A scholar is included among the top collaborators of Laura K. Shawver based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura K. Shawver. Laura K. Shawver is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ptacin, Jerod L., Carolina E. Caffaro, Hans R. Aerni, et al.. (2025). SAR-444245, an engineered not-alpha IL-2 leveraging synthetic biology, modulates critical components of the immune system for durable anti-tumoral activity. The Journal of Immunology. 214(10). 2781–2795.

Ptacin, Jerod L., Carolina E. Caffaro, Hans R. Aerni, et al.. (2021). An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism. Nature Communications. 12(1). 4785–4785. 84 indexed citations

Assimon, Victoria A., Jesse D. Vargas, Grace J. Lee, et al.. (2019). CB-6644 Is a Selective Inhibitor of the RUVBL1/2 Complex with Anticancer Activity. ACS Chemical Biology. 14(2). 236–244. 63 indexed citations

Milla, Marcos E., Jerod L. Ptacin, L. Ma, et al.. (2019). THOR-707, a novel not-alpha IL-2, promotes all key immune system anti-tumoral actions of IL-2 without eliciting vascular leak syndrome (VLS). Annals of Oncology. 30. v501–v501. 8 indexed citations

Zhou, Han-Jie, Jinhai Wang, Bing Yao, et al.. (2015). Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083). Journal of Medicinal Chemistry. 58(24). 9480–9497. 146 indexed citations

Shawver, Laura K., Dennis J. Slamon, & Axel Ullrich. (2002). Smart drugs: Tyrosine kinase inhibitors in cancer therapy. Cancer Cell. 1(2). 117–123. 409 indexed citations

Lenferink, Anne E.G., Jean F. Simpson, Laura K. Shawver, et al.. (2000). Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-α bigenic mice. Proceedings of the National Academy of Sciences. 97(17). 9609–9614. 112 indexed citations

Cherrington, Julie M., Laurie M. Strawn, & Laura K. Shawver. (2000). New paradigms for the treatment of cancer: The role of anti-angiogenesis agents. Advances in cancer research. 79. 1–38. 158 indexed citations

Fong, T. Annie T., Laura K. Shawver, Li Sun, et al.. (1999). SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.. PubMed. 59(1). 99–106. 885 indexed citations breakdown →

10.

Strawn, Laurie M. & Laura K. Shawver. (1998). Tyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials. Expert Opinion on Investigational Drugs. 7(4). 553–573. 57 indexed citations

11.

Arteaga, Carlos L., et al.. (1997). Unliganded Epidermal Growth Factor Receptor Dimerization Induced by Direct Interaction of Quinazolines with the ATP Binding Site. Journal of Biological Chemistry. 272(37). 23247–23254. 130 indexed citations

12.

Liu, Hao, Beatrice Langton-Webster, Jianhua Xuan, et al.. (1995). Construction of a Chimeric Antibody with Therapeutic Potential for Cancers Which Overexpress c-erbB-2. Biochemical and Biophysical Research Communications. 211(3). 792–803. 2 indexed citations

13.

Shawver, Laura K., Laurie M. Strawn, & Axel Ullrich. (1995). Membrane bound receptor tyrosine kinases and chemical carcinogenesis. Mutation research. Fundamental and molecular mechanisms of mutagenesis. 333(1-2). 23–28. 5 indexed citations

14.

Shawver, Laura K., et al.. (1994). Ligand-like effects induced by anti-c-erbB-2 antibodies do not correlate with and are not required for growth inhibition of human carcinoma cells.. PubMed. 54(5). 1367–73. 28 indexed citations

15.

Millauer, B, et al.. (1994). Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature. 367(6463). 576–579. 1036 indexed citations breakdown →

16.

Langton-Webster, Beatrice, et al.. (1991). A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines.. PubMed. 51(17). 4575–80. 200 indexed citations

17.

Nori, Mukund, Laura K. Shawver, & Michael J. Weber. (1990). A Swiss 3T3 Variant Cell Line Resistant to the Effects of Tumor Promoters Cannot Be Transformed by src. Molecular and Cellular Biology. 10(8). 4155–4162. 21 indexed citations

18.

Shawver, Laura K. & Thomas F. Deuel. (1990). Nuclear pp64 is phosphorylated in both serine/threonine and tyrosine through complex pathways regulated by 12-O-tetradecanoylphorbol-13-acetate and platelet-derived growth factor. Biochemical and Biophysical Research Communications. 167(3). 918–926. 1 indexed citations

19.

Shires, Thomas K., et al.. (1987). Immunoquantitation of cytochrome b5 and methylcholanthrene-induced cytochromes P-450.. PubMed. 46(8). 2567–74. 2 indexed citations

20.

Seidel, Sharon L., Laura K. Shawver, & Thomas K. Shires. (1984). Detection of phenobarbital-induced cytochrome P-450 in rat hepatic microsomes using an enzyme-linked immunosorbent assay. Archives of Biochemistry and Biophysics. 229(2). 519–531. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact